medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Number 1

<< Back Next >>

Ann Hepatol 2007; 6 (1)

End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage

Contreras AM, Ruiz I, Polanco-Cruz G, Monteón FJ, Celis A, Vázquez G, Gómez-Herrera E, García-Correa JE, Male-Velázquez R, Ruelas-Hernández S

Language: English
References: 37
Page: 48-54
PDF size: 106.17 Kb.


Text Extraction

Background and aim: To what extent the serum levels of alanine aminotransferase (ALT) are related to histological characteristics of liver damage caused by hepatitis C virus (HCV) infection among patients with end-stage renal disease (ESRD) remains unclear. Methods: Patients with a positive anti-HCV antibody titer confirmed by supplemental tests were evaluated by liver biopsy. We compared ALT levels in patients with and without renal damage, with similar histological grades and stages of inflammation and fibrosis. Patients were divided into two groups: patients with ESRD (n = 25) and patients without renal damage (n = 39). Results: The ALT level was 42.1 ± 24.3 IU/L for the ESRD group, compared with 109.9 ± 55.8 IU/L for the non-ESRD group (P ‹ 0.001). Liver inflammation (modified Knodell grade) was 4.0 ± 2.1 in the ESRD group versus 5.2 ± 2.4 in the non-ESRD group; fibrosis (6-point scale) was 1.1 ± 1.2 versus 1.7 ± 1.5, respectively. Conclusions: Despite histological evidence of liver inflammation, ALT levels in the ESRD group were normal, while ALT levels were significantly higher in the non-ESRD group with similar levels of liver inflammation. In conclusion, ALT levels are not a useful indicator of HCV infection in patients with ESRD and liver biopsies should be recommended for kidney transplant candidates.


REFERENCES

  1. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.

  2. Contreras AM. Viral hepatitis C in patients with renal disease. Rev Gastroenterol Mex 2002; 67(Suppl): S88-92.

  3. González-Michaca L, Mercado A, Gamba G. Hepatitis C en pacientes con insuficiencia renal crónica terminal. I Prevalencia. Rev Invest Clin 2000; 52: 246-54.

  4. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C infection in hemodialysis patients. Am J Kidney Dis 2005; 46: 290-300

  5. Méndez-Sánchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico city, Mexico. J Clin Microbiol 2004; 42: 4321-22.

  6. Monteón FJ, Gómez B, Valdespino C, Chavez S, Sandoval M, Flores A, Herrera R, et al. The kidney transplant experience at Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara México, In: Cecka JM, Terasaki P, Eds. Clinical Transplants 2003. UCLA Immunogenetics Center, Los Angeles; 2003: 165-74.

  7. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, Bellis L, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.

  8. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C. Hepatology 2002; 36: 973-7.

  9. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, Locatelli F. Decreased serum aminotransferase activity in patients with chronic renal failure: Impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 1009-15.

  10. Saab S, Brezina M, Gitnick G, Martin P, Yee HF Jr. Serum alanine aminotransferases in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis 2001; 37: 308-15.

  11. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, Jensik S, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191-5.

  12. Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills AS, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94(12): 3576-82.

  13. Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-9.

  14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  15. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.

  16. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  17. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.

  18. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.

  19. Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005; 100: 2010-8.

  20. Boyacioglu S, Gur G, Yilmaz U, Korkmaz M, Demirhan B, Bilezikci B, Ozdemir N. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc 2004; 36: 50-2.

  21. Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M, Ranghino A, et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999; 56: 2286-91.

  22. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.

  23. Stanley AJ, Haydon GH, Piris J, Jarvis LM, Hayes PC. Assessment of liver histology in patients with hepatitis C and normal transaminase levels. Eur J Gastroenterol Hepatol 1996; 8: 869-72.

  24. Vargas VF. Hepatitis C: risk factors. Rev Gastroenterol Mex 2002; 67(Suppl): S9-10.

  25. Contreras AM, Chung RT. Hepatitis C virus in solid organ transplantation: not always a bad thing. Gastroenterology 2002; 123: 1729-33.

  26. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57.

  27. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69: 1479-84.

  28. Glicklich D, Thung SN, Kapoian T, Tellis V, Reinus JF. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol 1999; 94: 159-63.

  29. Ahmad A, Hasan F, Abdeen S, Sheikh M, Kodaj J, Nampoory MR, Johny KV, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15: 257-60.

  30. Bañares R, Alonso S, Catalina MV, Casado M, Rincón D, Salcedo M, Álvarez E, et al. Randomized controlled trial of aspiration needle versus automated biopsy device for transjugular liver biopsy. J Vasc Interv Radiol 2001; 12: 583-87.

  31. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, et al. Peginterferon Alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.

  32. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.

  33. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  34. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.

  35. Pawlotsky JM. Use and interpretation of virological tests for Hepatitis C. Hepatology 2002; 36: S65-S73.

  36. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver International 2006; 26(9): 1095-9.

  37. Perez RM, Ferreira AS, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection? Clin Transplant 2005; 19(5): 622-5.




2020     |     www.medigraphic.com